论文部分内容阅读
[目的]研究早期乳腺癌外周血中CEA mRNA阳性循环肿瘤细胞的临床意义。[方法]检测50例早期乳腺癌患者、24例乳腺良性疾病患者和20例健康志愿者外周血CEA mRNA阳性细胞。[结果]早期乳腺癌患者外周血CEA mRNA阳性率为14.0%,CEA mRNA阳性率与TNM分期(P=0.004)、肿瘤大小(P=0.027)、血清CEA(P=0.000)水平异常升高显著性相关。CEA mRNA阳性患者中位无瘤生存期为18个月,与阴性患者比较差异有统计学意义(P=0.000)。[结论]CEA mRNA阳性循环肿瘤细胞可能是早期乳腺癌患者监测复发转移的重要指标和独立的预后因素。
[Objective] To study the clinical significance of CEA mRNA positive circulating tumor cells in peripheral blood of early breast cancer. [Method] Peripheral blood CEA mRNA positive cells were detected in 50 patients with early breast cancer, 24 patients with benign breast disease and 20 healthy volunteers. [Results] The positive rate of CEA mRNA in peripheral blood of patients with early breast cancer was 14.0%. The positive rate of CEA mRNA was significantly higher than that of TNM stage (P = 0.004), tumor size (P = 0.027) and serum CEA (P = 0.000) Sex related. The median tumor-free survival of CEA mRNA-positive patients was 18 months, which was significantly different from that of negative patients (P = 0.000). [Conclusion] CEA mRNA positive circulating tumor cells may be an important indicator to monitor recurrence and metastasis in patients with early stage breast cancer and an independent prognostic factor.